Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALT NASDAQ:AVTE NASDAQ:HUMA NASDAQ:PROK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.11+3.0%$2.89$2.56▼$6.44$587.31M0.254.63 million shs3.52 million shsAVTEAerovate Therapeutics$22.45+5.4%$21.05$89.95▼$99.05$650.71M0.9553,591 shs1.04 million shsHUMAHumacyte$0.73-4.9%$1.00$0.55▼$2.84$171.15M2.5217.78 million shs7.00 million shsPROKProKidney$1.84-5.6%$1.80$1.53▼$7.13$589.02M1.611.37 million shs1.02 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-1.95%-0.17%+11.44%-10.39%-31.83%AVTEAerovate Therapeutics-0.98%-3.66%+25.74%+30.20%+91.20%HUMAHumacyte+0.04%-1.22%-42.90%+18.33%-64.31%PROKProKidney-2.01%-4.41%+8.33%+5.41%+221.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALTAltimmune$3.11+3.0%$2.89$2.56▼$6.44$587.31M0.254.63 million shs3.52 million shsAVTEAerovate Therapeutics$22.45+5.4%$21.05$89.95▼$99.05$650.71M0.9553,591 shs1.04 million shsHUMAHumacyte$0.73-4.9%$1.00$0.55▼$2.84$171.15M2.5217.78 million shs7.00 million shsPROKProKidney$1.84-5.6%$1.80$1.53▼$7.13$589.02M1.611.37 million shs1.02 million shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALTAltimmune-1.95%-0.17%+11.44%-10.39%-31.83%AVTEAerovate Therapeutics-0.98%-3.66%+25.74%+30.20%+91.20%HUMAHumacyte+0.04%-1.22%-42.90%+18.33%-64.31%PROKProKidney-2.01%-4.41%+8.33%+5.41%+221.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALTAltimmune 2.55Moderate Buy$15.71405.28% UpsideAVTEAerovate Therapeutics 0.00N/AN/AN/AHUMAHumacyte 2.75Moderate Buy$6.25752.43% UpsidePROKProKidney 2.71Moderate Buy$9.00389.13% UpsideCurrent Analyst Ratings BreakdownLatest HUMA, AVTE, ALT, and PROK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2026PROKProKidney Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/24/2026ALTAltimmune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/22/2026ALTAltimmune Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.006/17/2026HUMAHumacyte TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$1.50 ➝ $1.256/16/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.006/11/2026HUMAHumacyte HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $4.006/8/2026HUMAHumacyte BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.006/2/2026ALTAltimmune CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform6/1/2026HUMAHumacyte BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSpeculative Buy$2.005/26/2026HUMAHumacyte HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$3.005/18/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.00 ➝ $20.00(Data available from 7/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALTAltimmune$40K15,120.04N/AN/A$1.99 per share1.56AVTEAerovate TherapeuticsN/AN/AN/AN/A$3.96 per shareN/AHUMAHumacyte$2.04M79.80N/AN/A$0.02 per share36.66PROKProKidney$890K624.48N/AN/A($3.36) per share-0.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALTAltimmune-$88.09M-$0.93N/AN/AN/A-214,860.98%-42.57%-35.57%8/11/2026 (Estimated)AVTEAerovate Therapeutics-$75.52M-$1.70N/AN/AN/AN/A-90.19%-77.47%N/AHUMAHumacyte-$40.83M-$0.57N/AN/AN/A-4,836.06%-2,914.18%-89.45%8/10/2026 (Estimated)PROKProKidney-$68.99M-$0.53N/AN/AN/A-8,131.50%N/A-21.39%8/11/2026 (Estimated)Latest HUMA, AVTE, ALT, and PROK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026PROKProKidney-$0.13-$0.14-$0.01-$0.14$0.10 million$0.23 million5/13/2026Q1 2026ALTAltimmune-$0.25-$0.18+$0.07-$0.18$0.00 millionN/A5/13/2026Q1 2026HUMAHumacyte-$0.10-$0.09+$0.01-$0.09$1.46 million$0.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALTAltimmuneN/AN/AN/AN/AN/AAVTEAerovate TherapeuticsN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/APROKProKidneyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALTAltimmune0.1229.5629.56AVTEAerovate TherapeuticsN/A8.788.78HUMAHumacyte5.463.933.32PROKProKidneyN/A9.069.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALTAltimmune78.05%AVTEAerovate TherapeuticsN/AHUMAHumacyte44.71%PROKProKidney51.59%Insider OwnershipCompanyInsider OwnershipALTAltimmune1.60%AVTEAerovate Therapeutics24.90%HUMAHumacyte3.10%PROKProKidney39.83%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALTAltimmune50194.47 million191.36 millionOptionableAVTEAerovate Therapeutics2028.99 million21.69 millionOptionableHUMAHumacyte150222.02 million215.14 millionOptionablePROKProKidney3302.06 million181.75 millionOptionableHUMA, AVTE, ALT, and PROK HeadlinesRecent News About These CompaniesProKidney Corp. (NASDAQ:PROK) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 30, 2026 | americanbankingnews.comWhy ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval PathJune 17, 2026 | insidermonkey.comProKidney names first chief technology officer as kidney therapy nears pivotal trial readoutJune 2, 2026 | bizjournals.comProKidney Appoints Kenneth Locke as Chief Technical OfficerJune 2, 2026 | globenewswire.comProKidney shareholders reaffirm board and auditor at 2026 meetingMay 29, 2026 | tipranks.comProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue EstimatesMay 15, 2026 | zacks.comProKidney Corp. Reports Phase 3 PROACT 1 Study Enrollment Progress and Q1 2026 Financial ResultsMay 15, 2026 | quiverquant.comQProKidney Reports First Quarter 2026 Financial Results and Business HighlightsMay 15, 2026 | globenewswire.comProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for RilparencelMay 2, 2026 | finance.yahoo.comProKidney Corp. Class AApril 14, 2026 | edition.cnn.comApril 2026 Penny Stock HighlightsApril 3, 2026 | finance.yahoo.comWhat Makes ProKidney Corp. (PROK) So AttractiveMarch 31, 2026 | insidermonkey.comWhat makes ProKidney Corp. (PROK) so attractiveMarch 31, 2026 | msn.com5 Best Penny Stocks That Could Triple Your MoneyMarch 30, 2026 | insidermonkey.comProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial OfficerMarch 25, 2026 | globenewswire.comProKidney Corp. (NASDAQ:PROK) Given Consensus Recommendation of “Moderate Buy†by BrokeragesMarch 22, 2026 | defenseworld.netDProKidney narrows loss to $150M as it eyes crucial kidney treatment trial resultsMarch 20, 2026 | bizjournals.comTrade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial StabilityMarch 20, 2026 | tipranks.comProKidney Reports Full Year 2025 Financial Results and Business HighlightsMarch 19, 2026 | finance.yahoo.com3 Promising Penny Stocks With At Least $600M Market CapFebruary 12, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhat to Expect From Q2 Earnings as Tech Strength BroadensBy Thomas Hughes | June 14, 2026SpaceX Valuation Loses Altitude as AI Risks MountBy Jeffrey Neal Johnson | June 23, 2026Flying Under the Radar: Lockheed Martin's $2.8B Stealth SetupBy Jeffrey Neal Johnson | June 17, 2026Beyond the AI Trade: 3 Defensive Stocks Built for StabilityBy Thomas Hughes | June 20, 2026Cerebras Systems, Inc: The Next Rags-to-Riches AI Story?By Thomas Hughes | June 25, 2026HUMA, AVTE, ALT, and PROK Company DescriptionsAltimmune NASDAQ:ALT$3.11 +0.09 (+2.98%) Closing price 04:00 PM EasternExtended Trading$3.10 -0.01 (-0.19%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Aerovate Therapeutics NASDAQ:AVTE$22.45 +1.15 (+5.40%) As of 07/7/2026Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.Humacyte NASDAQ:HUMA$0.73 -0.04 (-4.89%) Closing price 04:00 PM EasternExtended Trading$0.74 +0.00 (+0.52%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.ProKidney NASDAQ:PROK$1.84 -0.11 (-5.64%) Closing price 04:00 PM EasternExtended Trading$1.88 +0.04 (+2.45%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Exxon Could Be the Market's Next Big Comeback Stock Why Penguin Solutions May Be the Smartest AI Infrastructure Stock The Market Just Got Shaken—These 3 ETFs May Come Out Stronger Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns A Market Panic Just Discounted the AI Highway's Tollbooth Vertex’s Crinetics Deal Balances Growth with Integration Risk Apple and Broadcom Forge a Decade-Long Silicon Fortress These 3 Cash-Flow Stocks Give Investors More Than Just Growth Potential Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
